| Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression N Bobrovitz, H Ware, X Ma, Z Li, R Hosseini, C Cao, A Selemon, ... The Lancet Infectious Diseases 23 (5), 556-567, 2023 | 335 | 2023 |
| Global seroprevalence of SARS-CoV-2 antibodies: a systematic review and meta-analysis N Bobrovitz, RK Arora, C Cao, E Boucher, M Liu, C Donnici, ... PloS one 16 (6), e0252617, 2021 | 243 | 2021 |
| SeroTracker: a global SARS-CoV-2 seroprevalence dashboard RK Arora, A Joseph, J Van Wyk, S Rocco, A Atmaja, E May, T Yan, ... The Lancet Infectious Diseases 21 (4), e75-e76, 2021 | 229 | 2021 |
| Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies I Bergeri, MG Whelan, H Ware, L Subissi, A Nardone, HC Lewis, Z Li, ... PLoS medicine 19 (11), e1004107, 2022 | 168* | 2022 |
| SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021 HC Lewis, H Ware, M Whelan, L Subissi, Z Li, X Ma, A Nardone, ... BMJ Global Health 7 (8), e008793, 2022 | 112 | 2022 |
| Lessons from a rapid systematic review of early SARS-CoV-2 serosurveys N Bobrovitz, RK Arora, T Yan, H Rahim, N Duarte, E Boucher, JV Wyk, ... MedRxiv, 2020.05. 10.20097451, 2020 | 56 | 2020 |
| Adapting serosurveys for the SARS-CoV-2 vaccine era N Duarte, M Yanes-Lane, RK Arora, N Bobrovitz, M Liu, MG Bego, T Yan, ... Open forum infectious diseases 9 (2), ofab632, 2022 | 41 | 2022 |
| Spatial transcriptomics reveals distinct and conserved tumor core and edge architectures that predict survival and targeted therapy response R Arora, C Cao, M Kumar, S Sinha, A Chanda, R McNeil, D Samuel, ... Nature Communications 14 (1), 5029, 2023 | 19 | 2023 |
| ROSES‐S: Statement from the World Health Organization on the reporting of seroepidemiologic studies for SARS‐CoV‐2 World Health Organization Seroepidemiology Technical Working Group Influenza and other respiratory viruses 15 (5), 561-568, 2021 | 17 | 2021 |
| Unity Studies Collaborator Group. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies I Bergeri, MG Whelan, H Ware, L Subissi, A Nardone, HC Lewis, Z Li, ... PLoS Med 19 (11), e1004107, 2022 | 16 | 2022 |
| SeroTracker‐RoB: A decision rule‐based algorithm for reproducible risk of bias assessment of seroprevalence studies N Bobrovitz, K Noël, Z Li, C Cao, G Deveaux, A Selemon, DA Clifton, ... Research Synthesis Methods 14 (3), 414-426, 2023 | 9* | 2023 |
| NCBP2 and TFRC are novel prognostic biomarkers in oral squamous cell carcinoma R Arora, L Haynes, M Kumar, R McNeil, J Ashkani, SC Nakoneshny, ... Cancer Gene Therapy 30 (5), 752-765, 2023 | 8 | 2023 |
| Student-run academic journals in STEM: A growing trend in scholarly communication K Ng, MH Asadi-Lari, SWS Chan, RK Arora, F Qaiser, V Sharlandjieva, ... Science Editor 40 (2), 130-135, 2017 | 8 | 2017 |
| A systematic review and meta-analysis of SARS-CoV-2 seroprevalence studies aligned with the WHO population-based sero-epidemiological ‘Unity’protocol CRD42020183634, 2021 N Bobrovitz, RK Arora, E Boucher, T Yan, H Rahim, J Van Wyk PROSPERO, 2021 | 6 | 2021 |
| Lessons from the pandemic: Responding to emerging zoonotic viral diseases—a Keystone Symposia report J Cable, A Fauci, WE Dowling, S Günther, DA Bente, PD Yadav, ... Annals of the New York Academy of Sciences 1518 (1), 209-225, 2022 | 5 | 2022 |
| Timeliness of reporting of SARS-CoV-2 seroprevalence results and their utility for infectious disease surveillance C Donnici, N Ilincic, C Cao, C Zhang, G Deveaux, D Clifton, D Buckeridge, ... Epidemics 41, 100645, 2022 | 5 | 2022 |
| Rapid antigen tests for SARS-CoV-2 M Liu, RK Arora, M Krajden CMAJ 193 (13), E447-E447, 2021 | 5* | 2021 |
| Occupation and SARS-CoV-2 seroprevalence studies: a systematic review E Boucher, C Cao, S D’Mello, N Duarte, C Donnici, N Duarte, G Bennett, ... BMJ open 13 (2), e063771, 2023 | 4 | 2023 |
| Limitations introduced by a low participation rate of SARS-CoV-2 seroprevalence data O Pluss, H Campbell, L Pezzi, I Morales, Y Roell, TM Quandelacy, ... International Journal of Epidemiology 52 (1), 32-43, 2023 | 3 | 2023 |
| Serology assays used in SARS-CoV-2 seroprevalence surveys worldwide: a systematic review and meta-analysis of assay features, testing algorithms, and performance X Ma, Z Li, MG Whelan, D Kim, C Cao, M Yanes-Lane, T Yan, T Jaenisch, ... Vaccines 10 (12), 2000, 2022 | 3 | 2022 |
Niklas BobrovitzUniversity of CalgaryVerified email at ucalgary.ca
